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ABSTRACT  
Objective: Developing novel non-ionic microemulsions (MEs) for transdermal of atenolol as satisfactory alternative drug delivery systems for the oral route.  
Methods: Seven MEs were developed then checked for encapsulation of atenolol using Fourier Transform Infrared Spectroscopy (FTIR-
spectroscopy) (), isotropy, droplet sizes, rheological properties and transdermal flux using Franz diffusion cell. Furthermore, two MEs with best flux 
values were selected for bioavailability evaluation after transdermal application over rat’s skin.  
Results: The results showed that the MEs complies with colloidal systems properties. Also, the developed MEs were stable throughout the study, 
ideal viscous systems with droplet sizes below 500 nm and isotropic. Besides, FTIR-spectra could reveal the structure of the MEs and encapsulation 
of atenolol inside the dispersed phase. Moreover, the flux values of atenolol in MEs through rat’s skin varied with different factors such as atenolol 
concentration, MEs’s composition, and zetapotential. The highest flux value of the developed systems was 243.5±16.3 µg. cm-2. h-1. Furthermore, the 
in vivo results showed that using the two tested microemulsions maximum plasma levels of atenolol 5.22±0.43 and 4.06±0.15 mg. ml-1
Conclusion: The developed microemulsions can be promise formulations for transdermal administration of atenolol as alternative for oral tablets.  
at 8.18 and 
3.64 h respectively could be achieved.  
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Atenolol is a β1-selective adrenergic blocking agent. It is widely used 
in the management of hypertension as monotherapy or in 
combination with other classes of antihypertensive agents [1-4]. 
Atenolol subjects to extensive first-pass hepatic metabolism and has 
an absolute oral bioavailability of about 50–60%. Moreover, it was 
reported that, in the case of oral administration, atenolol can induce 
side effects such as diarrhea, ischemic colitis and mesenteric arterial 
thrombosis [5-8]. Transdermal application of a drug such as atenolol 
can lower the total daily dose and eliminate the gastrointestinal side 
effects. Also, the ease and self-medication can improve the patient 
compliance [8, 9]. The short biological half-life (2.8-7.4 h) and lower 
value of molecular weight (266 g. mole-1
MATERIALS AND METHODS  
) renders atenolol as an 
ideal candidate for transdermal drug delivery systems [10]. 
Many studies investigated the transdermal of atenolol using 
iontophoresis and chemical penetration enhancers [11-15]. Other 
studies evaluated the transdermal of atenolol such as using gel 
formulation, ethylene-vinyl acetate matrix or hydroxyl propyl 
methyl cellulose and ethyl cellulose matrix [16-18]. 
Newtonian rheological properties and high penetration enhancing 
the capacity of microemulsions (MEs) make them ideal carriers for 
transdermal as well as oral use [19-22]. Only one study was 
reported about in vitro investigation of the transdermal of atenolol 
using W/O microemulsion as a carrier. In this study, many lipophilic 
surfactants such as capmul GMO50, caprol ET, lauroglycol 90 were 
screened to evaluate their propensity for emulsification of the 
aqueous phase to optimize atenolol loading [23]. The present study 
aimed to develop novel colloidal delivery systems using nonionic 
surfactants to enable and improve the transdermal application of 
atenolol and evaluate their bioavailability in vitro and in vivo. 
Materials 
Atenolol was offered from a local company (United Pharmaceutical 
Manufacturing Co.). Ethanol HPLC grade was purchased from scientific 
and chemicals supplies LTD (Bilston, UK). Methanol HPLC grade was 
purchased from Fulltime (Anqing, China). Water for HPLC was 
purchased from LabChem (Zelienople, USA). Dimethyl sulfoxide (DMSO) 
was purchased from AZ Chem (Ontario, Canada). Sorbitan monolaurate 
(SpanP®P 20) and Poloxyethylenesorbitan. Mono-oleate (TweenP®P 80) were 
purchased from SIGMA (Lyon, France). Citric acid (CA) and Isopropyl 
Myristate (IPM) were purchased from Merck (Darmstadt, Germany). 
Instruments and methods  
Microemulsions (MEs) preparation  
MEs were prepared by the titration method [24]. Atenolol was dissolved 
in the hydrophilic phase composed of a mixture of water and ethanol or 
water, ethanol and DMSO. Two ml of IPM was added to atenolol solution. 
Either span 20 or mixture of span 20: tween 80 (3:2) were added 
dropwise with continuous stirring over magnetic stirrer to the lipophilic 
and hydrophilic phase mixture until a clear microemulsion was formed. 
The added amounts of surfactants were recorded. Compositions of the 
developed microemulsions are listed in table 1. 
Pseudo-ternary phase diagrams of microemulsion systems  
A pseudo-ternary phase diagram was plotted to find the existence area of 
MEs. Another three-phase diagram for MEs with 100 mg atenolol was 
accomplished for testing the influence of atenolol on this area. 
Formulations were made using three components which are the 
hydrophilic phase, lipophilic phase, and surfactants. Each phase forms 
one face of the triangle. The formulations were made with fractions of 
the three components according to crossing points which formed by 
plotting three parallel lines to the three faces of the triangle. More 
formulations were made between the cross points on the border of MEs 
area. After mixing, clear and stable formulations were identified to be 
MEs [24]. 
Viscosity measurement 
An electric Rheometer made by Anton Paar, universal tool, model 
MCR 301 (Ostfildern, Germany) was used to determine the viscosity 
and rheological properties of MEs. Rheograms were established for 
the MEs with increasing and decreasing shear force at 25 °C on the 
bob and cup viscometers. 
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Table 1: Composition of different developed MEs containing atenolol. 
MEs Lipophilic phase 
(IPM) (ml) 








ME600ts 2  3.9 (Eth: W) (70:30) 600  2.2 (T: S) (3:2)  74.07 
ME800ts 2 5.1 (Eth: W) (70:30)  800  3.1 (T: S) (3:2)  78.43  
ME1000-0.1CA 2  4.5 (Eth: W) (70:30) 0.1M CA 1000  2.9 (T: S) (3:2)  106.38  
ME900-1CA0.7 2  1.6 (Eth: W) (70:30) 1M CA 900  0.1 (T: S) (3:2)  243.24  
ME900-1CA0.3 2  3 (Eth: W) (30:70) 1M CA 900  1.4 (T: S) (3:2)  140.62  
ME1000dmso-s 2  5 (Eth: W: DMSO) (70:15:15)  1000  3.7 S 93.45  
ME1000dmso-ts 2  5 (Eth: W: DMSO) 
(70:15:15)  
1000  2.9 (T: S) (3:2)  
 
101.01  
Eth: ethanol, w: water, DMSO: Dimethyl sulfoxide, IPM: Isopropyl Myristate, CA: citric acid, T: Tween 80, S: Span 20.  
  
Droplet size measurement (Zeta-potential measurement) 
A laser doppler electrophoresis was carried out on the 
microemulsions with a Zeta-sizer made by Microtrac (Pennsylvania, 
USA) equipment which is capable of measuring particle size ranging 
between 0.8 nm to 6.54 µm, Zeta potential range-125 to+125 mV. 
The sample was introduced into the apparatus cell without dilution 
as the formation of microemulsions depends on the concentration. 
Samples were measured at a temperature of 32 °C without filtration. 
Polarized microscope 
A polarized microscope model ML9030 made by MEIJI techno (Saitama, 
Japan) was used for testing the isotropy of the microemulsions.  
Fourier transform infrared spectroscopy (FTIR) measurements 
The encapsulation of atenolol, as well as the structure of the MEs, was 
assessed by recording spectra by FTIR-spectrometer UATR Two, 
Li600301 spectrum made by Perkin Elmer in LIantrisant, UK for each 
single component, ME with atenolol and ME without atenolol. The FTIR-
spectra were measured at wave numbers between 450 and 4500 cm-1. 
Preparing rat’s skin 
Wistar male rats were purchased originally from the University of Jordan 
and fertilized at an animal house at Isra University. All the procedures 
were carried out in harmony with the NIH guidelines for the care and use 
of laboratory animals which were approved by the Animal Ethics 
Committee of Isra University. The rats were shaved carefully before 
executing. The adipose tissues were removed from the peeled skin and 
excised to small pieces to fit with Franz diffusion cell surface area (with 
the diameter a bit larger than 10 mm) then were washed with buffer and 
stored in a deep freeze at a temperature below than-70 °C. 
In vitro study of transdermal of atenolol using franz cell 
Franz diffusion cell is usually used for studying drug permeation 
through excised animal’s skin [25]. Three Franz diffusion cells made 
by Orchid scientific in India (10 mm diameter, 5 ml acceptor 
volume) were used at the same time to study the transdermal of 
atenolol in MEs for each formulation. The cells were connected with 
the circulatory water bath to adjust the temperature of the cells at 
32±0.1 °C. The frozen rat’s skin pieces were thawed in a water bath 
at 32 °C immediately before using it in Franz-diffusion cells. The skin 
pieces were fixed directly over the acceptor compartment medium 
in contact with the acceptor medium. The acceptor compartment 
was filled with 5 ml of 75% methanol in water. Only 0.2 ml of each 
microemulsion was allocated over the skin using an insulin syringe. 
Half ml samples were withdrawn from the acceptor’s orifice after 1, 
3, 5, 7 and 24 h for analyzing the penetrated drug through the skin 
using HPLC. Each time withdrawn samples were replaced by 0.5 ml 
of the same acceptor medium.  
In vivo study of transdermal of atenolol in rats 
Half ml of each of ME1000dmso-sor ME1000-0.1CAwas applied over 
shaved area of 4 cm2 on the back of each of 4 rats weighing 270-300g for 
each formulation. Blood samples (0.5 ml) were collected from the rats 
periodically after 1, 3, 7. 11, 15, 19, and 24 h in EDTA-blood-tubes. The 
blood samples were centrifuged at 4000 rpm at 4 °C for 20 min. The 
plasma portions were transferred into new tubes then 1 ml of ethanol 
was added to each tube. The tubes were centrifuged at a rate of 8000 
rpm at 4 °C for 20 min. The supernatant was filtered through 0.45 µm 
filter and transferred to HPLC sample tube for analysis. 
Atenolol analysis using a high-pressure liquid chromatography 
(HPLC) method 
Analysis was performed using chromatographic system of Thermo 
Scientific, Dionex Ultimate 3000 HPLC made in Germering, Germany 
connected with diode array detector using suitable standards. The 
samples were injected with a volume of 20 µl into the mobile phase of 
70% methanol at a flow rate of 0.5 ml/min and separated in column 
system C18 (4.6*250 mm). The detection was carried out at a 
wavelength of 224 nm [26]. A calibration curve was established for 
concentrations of 0.05, 0.1, 0.2, 0.4, 0.8, 1 and 2 mg. ml-1 to determine 
the amount of penetrated atenolol through the skin and in plasma.  
Pharmacokinetic and statistical analysis 
Tests were triplicated then the mean and standard deviation values 
calculated. Origen program was used for statistical evaluation with a 
confidence interval of 95%. Jss is the steady-state flux is estimated from 
the slope at the steady state line (eq1) of plotting the cumulative 
penetrated amount per cm2
tJAQ ss=
 (Q/A) against the time (t) as in eq. 1 [27]: 
 ………….………………………………….1 
Where: A: skin surface area and Q: the cumulative mass penetrating 
a membrane. 
The absorption rate constant, elimination rate constant and area 
under the curve were estimated from plasma level against time 
curve using pheonix®
RESULTS  
 program (Phoenix Version 8.0, Certara, L. P.) 
by applying one compartment open model. 
HPLC method and the calibration curve  
The plotted calibration curve for measured areas under the curve against 
the concentrations of atenolol for concentrations between 0.05-2 mg/ml 
(fig. 1A) showed linearity of 99.9% and regression standard deviation of 









lowest concentration in the calibration curve) as the signal height ratio of 
atenolol to the noise markedly higher than 9 [28]. 
The straight line equation number (eq. 2) was adopted to calculate 
of penetrated atenolol amount:  
A=1159.47 C+64.56 …………………………. (2) 
Where: A: Area under the peak and C: Atenolol concentration.  
For estimating the total amount of penetrated Atenolol the following 
developed equation (eq. 3) was developed:  
 ………………. (3) 
Three phase diagrams (Pseudoternary diagram) 
The three-phase diagrams were established for MEs composed of 
IPM, water, ethanol and a mixture of tween 80: span 20 (3:2) 
without atenolol (fig. 2A) and with 100 mg atenolol (fig. 2B). 
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Fig. 1: Chromatograms of atenolol using HPLC A: in standard solutions for concentration between 0.05-2 mg/ml; B: in samples taken from 
Franz diffusion cell after 1-24 h; C: in blood samples after transdermal application between 1-24 h 
 
 
Fig. 2: Three phase diagrams of microemulsions (MEs) composed of IPM, water and a mixture of span 20: tween 80 (2:3) A: without 
atenolol; B: with atenolol 
 
 
Fig. 3: Rheograms of developed MEs containing atenolol 
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The area of clear MEs free of atenolol was estimated at fractions 
more than 0.6 of IPM and less than 0.6 of hydrophilic phase. After 
addition of 100 mg of atenolol this area of ME was shifted to 
fractions less than 0.6 of IPM, more than 0.4 of hydrophilic phase 
and less than 0.6 of the surfactants. Consequently, the MEs 
containing atenolol consumed less surfactants amounts and 
solubilized higher hydrophilic phase fractions. 
Rheological properties 
The rheological properties were determined using the bob and cup 
instrument with increased shear rate for different systems and the 
results are represented in fig. 3. The rheograms of different 
formulations show that the shear rate against the viscosity was 




Fig. 4: Droplet size distribution curve of the ME1000 0.1CA using Zeta sizer 
 
Table 2: The measured mean droplets sizes, zata potential and polydisperisty index (PDI) of different formulated microemulsions using 
Zeta-sizer 
ME Mean droplet size (nm) PDI Zeta potential [mv]  
ME600ts 270.1±275 10.88 10.72 
ME800ts 163.6±60.4 6.20 12.29 
MEtsfree atenolol 52.2±19.4 2.14 -0.55 
ME1000-0.1CA 107.4±28 8.53 0.54 
ME900-1CA0.7 557±112 0.16 0.57 
ME900-1CA0.3 550±145 0.30 3.02 
MECA free Atenolol 162.9±56.1 0.27 1.83 
ME1000dmso-s 378±138 0.51 0.55 
ME1000dmso-ts 320±321 1.74 4.29 
MEdmso free Atenolol 139.2±41.8 0.56 16.8 
Data given in this table is presented as mean±SD, n=3, SD: Standard deviation, PDI: Polydispersity index 
 
 
Fig. 5: FTIR-spectra (Fourier transform infrared) of A: pure components which used in formulation the microemulsions atenolol,; B: 
microemulsion with atenolol and microemulsion without atenolol 
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Droplet size measurement 
The results of zeta sizer (fig. 4) including the mean zeta, zeta 
potential droplets size and poly disparity index of the MEs with 
atenolol are summarized in table 2. 
Loaded systems with atenolol containing only water and ethanol 
showed 270, 163 and high polydispersity index. Using 0.1 M citric 
acid solution reduced the droplet size to 107 nm in ME1000-0.1CA. 
However, droplets sizes were around 500 nm when 1 M citric acid 
solution was used in ME1000-1CA0.7 and ME1000-1CA0.3 with 
relatively low polydispersity index and zeta potential. Also, by 
means of DMSO as penetration enhancer increased the 
concentration of atenolol in MEs as well as the droplets sizes to 
exceed 300 nm. Measurements of the same three systems free of 
atenolol showed smaller droplet size in comparison to loaded 
systems with atenolol  
Incorporation of atenolol in the ME600st and ME800st increased the 
zeta potential with increasing atenolol concentration from negative 
in case of free atenolol system to 10.7 and 12.2 mV respectively. 
Addition of citric acid and DMSO neutralized the effect of atenolol 
and these MEs showed low zeta potential. However, using span 20 
alone showed lower zeta potential compared to span 20 and tween 
80 systems containing DMSO. Also, the decrease in ethanol fractions 
and an increase in water factions in system ME1000-1CA0.3 led to 
an increase the zeta potential compared to system ME1000-1CA0.7. 
Moreover, free atenolol ME containing DMSO showed high zeta 
potential (16 mV) in comparison to other free atenolol MEs. 
Studying of atenolol encapsulation using Fourier transform 
infrared spectroscopy (FTIR) 
FTIR was used for studying the structure of MEs. The spectra of the 
different pure single ingredient used in the formulation of ME are 
represented in fig. 5A. Also, the spectra of ME with atenolol, ME 
without atenolol and atenolol are represented together in fig. 5B.  
The different detected bands of the different components of MEs and 
their chemical bonds assignment are listed in table 3 [29]. 
 
Table 3: The most important detected bands of the different components of MEs and their chemical bonds assignments 
Bands (cmP-1 P) Assignment 
450-830 which observed in ME, tween 80 and span 20 spectra  C-C and C-H bending 
1045  C-O stretching of Ethanol  
1104  C-O stretching of IPM 
1092 in tween 80 and 1088 in span20 spectra  C-O stretching  
(disappeared to be weaker bands in IPM at 1118 and 1189 cmP-1P in ME spectra) 
1720-1740  C=O ester group stretching of IPM 
 2700 to 3000 C-H stretching of IPM 
3100-3671  OH, C-H stretching and bending 
 
ME-spectrum was similar to IPM-spectrum which represents the outer 
phase of the ME except for the band between 2700-3000 which is 
possibly related to carbon chains of span 20 and tween 80. The 
declining of C-O stretching and appearing C-H stretching indicates that 
sorbitol ring and an ester bond in tween 80 and span 20 oriented to 
inside the hydrophilic phase where carbon chains of the side groups 
oriented to the outer surface of the droplets in the outer phase. 
Moreover, FTIR-spectra of MEs with and without atenolol were similar 
and the bands of atenolol disappeared from ME-spectrum with AT. 
However, C-O stretching at wavelength 1045 cmP-1P of ethanol appeared 
in ME-FTIR-spectrum near of C-O stretching of IPM.  
Transdermal studying using Franz diffusion cell 
Seven MEs containing atenolol were developed to study the 
transdermal of atenolol using MEs as carriers. Ethanol was used as a 
cosolvent in the formulation. Also, 0.1 and 1 M citric acid solutions 
were added to the hydrophilic phase as a buffering agent to improve 
the solubility of atenolol in the hydrophilic phase in three of the 
developed MEs. Besides, the effect of DMSO as penetration enhancer 
atenolol was studied in two other MEs; one of them was stabilized 
with span 20 and the second with mixture of tween 80 and span 20. 
The in vitro transdermal testing for atenolol was performed using 
Franz diffusion cell through shaved rat’s skin over 24h. The 
penetrated atenolol was quantified by removing 0.5 ml samples 
from the acceptor and analyzing the musing HPLC (fig. 1B). 
Penetrated atenolol amounts per cmP2P were assessed over 24 h and 
the cumulative measured amounts per cmP2P plotted against the time. 
Transdermal profiles for different formulations are represented in 
fig. 6. 
The Flux (Jss) and lag time (tlag) were calculated from the slope and 
from intersect with time axis respectively of the line at steady state 
(eq.1). The results are tabulated in table 4. 
 
 
Fig. 6: Cumulative transdermal of atenolol from different formulated MEs over 24 h using Franz diffusion cell. Data given in this fig. is 
presented as mean±SD, n=3, SD: Standard deviation 
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Table 4: The flux of different formulated microemulsions (MEs) through rat’s skin using Franz diffusion cell 
MEs Flux (Jss) µg. cm-2. h Tlag (h) -1 
ME600ts 81.9±2.28 0.8 
ME800ts 111.8±5.7 0 
ME1000-0.1CA 243.5±16.3 3.5 
ME900-1CA0.7 123.3±19.2 0 
ME900-1CA0.3 111.7±42.1 2.4 
ME1000dmso-s 190.3±21.3 2.4 
ME1000dmso-ts 67.9±14.8 2.6 
Data given in this table is presented as mean±SD, n=3, SD: Standard deviation 
 
Tlag: lag time ME1000-0.1CA had the highest flux where the 
ME1000dmso-s had the second value of flux among developed 
microemulsions. ME800ts which has a similar composition as 
ME600ts but higher concentration showed an increase in flux from 
81.9 to 111.8 µg. cmP-2P. hP-1P. However, stabilization of microemulsion 
using span 20 and tween 80 in ME1000dmso-ts with the aid of 
DMSO as penetration enhancer reduced the flux from 190.3 to 67.9 
µg. cmP-2P. hP-1P. Moreover, the increase in the concentration of citric acid 
from 0.1 to 1 M to increase the solubility of atenolol and reverse the 
ratio of hydrophilic phase (ethanol: water) from 70:30 to 30:70 in 
ME900-1CA0.3and ME900-1CA0.7 respectively led to decrease in 
the flux.  
In vivo transdermal of atenolol loaded microemulsion 
penetration study 
The transdermal bioavailability of atenolol loaded microemulsion 
was studied by applying each of ME1000-0.1CA and system 
ME1000dmso-s which showed the best in vitro flux on 4 shaved rat’s 
skin. The penetrated amount of atenolol through the skin in plasma 
was quantified in 0.5 ml collected blood samples over 24 h using 
HPLC-method (fig. 1C). The two plasma level time curves over 24 h 
are represented in fig. 7. Furthermore, elimination rate constant 
half-life (K10_HL), the area under the curve (AUC), the absorption 
rate constant half-life (K01_HL), time of maximum absorption 
(tmax) and maximum concentration (Cmax) were calculated using 
phoenix program. Results are summarized in table 5. 
 
 
Fig. 7: Plasma level time curve of atenolol in rats from ME1000 0.1CA; and ME1000dmso-s. Data given in this fig. is presented as mean±SD, 
n=3, SD: Standard deviation 
 
Table 5: The different transdermal bioavailability parameters of atenolol using pheonix program including elimination rate constant 
half-life (K10_HL), the area under the curve (AUC), the absorption rate constant half-life (K01_HL), time of maximum absorption (tmax) 
and maximum concentration (Cmax) of ME1000m0.1CA and ME1000dmso-s 
Parameter Units ME1000-0.1CA CV% ME1000dmso-s CV% 
AUC mg. h. mlP-1 285.54±61.11 21.40 39.99±8.37 20.93 
K01_HL H 0.91±0.13 14.33 0.99±0.25 24.86 
K10_HL H 45±11.86 26.36 26.17±7.59 29.04 
CL_F ml. hP-1 1.84±0.39 21.42 11.69±2.45 20.95 
Tmax H 5.22±0.43 8.18 4.85±0.69 14.184 
Cmax mg. mlP-1 4.06±0.15 3.64 0.93±0.05 5.63 
Data given in this table is presented as mean±SD, n=3, SD: Standard deviation 
 
The maximum times of absorption and the absorption half-lives of 
the two MEs were similar. The maximum concentration of ME1000-
0.1CA was 4.06 mg. mlP-1P and in the case of ME1000dmso-s was 0.93 
mg. mlP-1P. Also, no lag time was observed for two formulated system. 
Furthermore, the calculated AUC showed higher bioavailability of 
ME1000-0.1CA more than 7 folds in comparison toME1000dmso-s. 
However, the plasma level of atenolol increased rapidly and 
decreased very slowly to remain relatively high at over 24 h.  
DISCUSSION  
Using FTIR-spectroscopy, incorporation of atenolol inside the MEs 
and distribution of ethanol in the external phase with IPM could be 
proved. Construction of three-phase diagram helps to prepare a 
stable homogeneous system of water and oil with as little surfactant 
as possible that can be diluted with water in all proportions without 
phase separation [30]. However, the observed shifting in required 
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fractions for forming clear MEs in the three-phase diagram towards 
more fractions of hydrophilic phase can be explained by the change 
in the polarity of the hydrophilic phase because of the presence of 
atenolol which led in its turn to change in the interfacial tension. As a 
result, the solubility of the hydrophilic phase was increased after the 
addition of atenolol. 
Furthermore, all systems had Newtonian properties with relatively 
low viscosity which impart them good favorable properties for 
penetration through the skin [31]. The viscosities of different 
formulations were similar and less than 0.1 Pa. s. However, ME900-
1CA0.7 showed the highest viscosity compared to other MEs which 
may be attributed to the small amount of used surfactants (0.1 ml) 
and hydrophilic phase volume (1.4 ml). The ME900-1CA0.3 had the 
lowest viscosity which may be related to the hydrophilic phase 
composition.  
The droplet size is an important factor in controlling the rate and 
extent of drug release as well as permeation of drugs through the 
skin. ME1000-0.1CA which had the smallest droplet size showed a 
good penetration through rat’s skin and a higher flux than other 
formulated systems  
The droplet size of the MEs varied between 100-500 nm which 
complied with the colloidal system’s characteristics [32]. 
Furthermore, low droplet size of free atenolol in comparison to the 
same composition loaded atenolol systems gave another proof of 
encapsulation of atenolol inside the inner phase.  
Hence, a sufficient volume of hydrophilic phase had to be used to 
solubilize atenolol before addition to 2 ml of lipophilic phase, the 
consumed surfactant amount varied with the varying volume of 
encapsulated hydrophilic phase and its composition.  
The in vitro transdermal using Franz diffusion cell didn’t show a 
consistent correlation between the flux and atenolol concentration in 
MEs according to fick’s law but was more related to MEs compositions 
of hydrophilic phase, surfactants type and droplet size [33]. 
Using 0.1M citric acid as buffering agent led to an increase the 
solubilized atenolol in ME, decrease the droplet size, decrease the 
zeta potential and increase in the flux. However, further increasing 
in citric acid concentration to 1M increases the incorporated 
atenolol and the droplet size. Hence, the flux of atenolol decreased. 
DMSO as penetration enhancer didn’t enhance the penetration in case 
of ME1000dmso-st. Conversely, DMSO enhanced the penetration of 
atenolol in system ME1000dmaso-s which was stabilized using span 
20 only which may be attributed to the small structure of span 20 in 
comparison to tween 80 and hydrophilic property of tween 80. 
Moreover, a greater volume of span 20 was consumed for stabilizing 
ME1000dmso-s in comparison to ME1000dmso-st which also may be 
related to a small structure of span 20. However, the developed 
microemulsion ME1000-0.1CA and ME1000dmso-s showed higher 
flux (243.5±16.3 and 190.3±21.3 µg. cm-2. h-1 respectively) in 
comparison to the reported best-developed microemulsions by 
Dhingani et al. (140.69 µg. cm-2. h-1) [23]. Furthermore, the evaluated 
AUC (12.4±3.06*10-3 mg. h. ml-1) of atenolol in ethylene-vinyl acetate 
(EVA) matrix system containing polyoxyethylene-2-oleyl ether was 
much lower than estimated in our study [17]. 
ME1000-0.1CA showed higher flux and bioavailability in comparison 
to ME1000dmso-s which may be associated to the lower droplet size 
and the higher concentration of atenolol in ME1000-0.1CA compared 
to ME1000dmso-s. Furthermore, the transdermal application of both 
two systems maintained a high plasma level over 24 h during the 
investigation. 
CONCLUSION  
The flux of atenolol didn’t correlate always with the concentration of 
atenolol. Contrariwise, it related with surfactant nature, the 
composition of the inner phase or even with zeta potential. However, 
the composition of MEs, their influence on zeta potential and the 
impact of their zeta potential on the transdermal (that the non-
ionized form is preferable for penetration through cell membranes) 
need more investigation. 
In the present study, atenolol could be incorporated successfully in novel 
microemulsions which showed rapid and high transdermal flux with a 
relatively constant and high plasma level of atenolol during 24 h. 
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